Abstract
There is mounting evidence that elevated circulating concentrations of glycated insulin play a role in insulin resistance in type 2 diabetes. This study evaluated the secretion of glycated insulin in response to enteral stimulation in type 2 diabetic subjects. Following a mixed meal (450 kcal; 44 % carbohydrate; 40 % fat; 16 % protein), glycated insulin rose 10-fold to peak (60 min) at 104.5 ± 25.0 pmol/l (p < 0.001), representing 22 % total circulating insulin. The response paralleled early rises in insulin and C-peptide, which peaked at 90 min and were more protracted. Maximum glucose concentrations were observed at 50 min. These data indicate that type 2 diabetic subjects exhibit a rapid meal-induced release of glycated insulin from readily releasable pancreatic beta-cell stores, which might contribute to impaired glucose homeostasis following enteral nutrition.
Key words
Glycated insulin - meal - type 2 diabetes
References
-
1
Unger R H, Grundy S.
Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: Implications of the management of diabetes.
Diabetologia.
1985;
28
119-121
-
2
Leahy J L.
B-cell dysfunction with chronic hyperglycaemia: overworked beta cell hypothesis.
Diabetes Revs.
1996;
4
298-319
-
3
Sato E, Mori F, Igarashi S, Abiko T, Takeda M, Ishika S, Yoshida A.
Corneal advanced glycation end products increase in patients with proliferative diabetic retinopathy.
Diabetes Care.
2001;
24
479-482
-
4
Schinzel R, Munch G, Heidland A, Sebekova K.
Advanced glycation end products in end-stage renal disease and their removal.
Nephron.
2001;
87
295-303
-
5
Aso Y, Inukai T, Tayama K, Takemura Y.
Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes.
Acta Diabetol.
2000;
37
87-92
-
6
Brownlee M.
Glycation and diabetic complications.
Diabetes.
1993;
43
836-841
-
7
Lyons T J, Jenkins A J.
Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis.
Diabetes Reviews.
1997;
5
365-391
-
8
Eizirik E L, Korbutt G S, Hellerstrom C.
Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the β-cell function.
J Clin Invest.
1992;
90
1263-1268
-
9
Svensson C, Sandler S, Hellerstrom C.
Lack of long term β-cell glucotoxicity in vitro in pancreatic islets isolated from two mouse strains (C57BL/6J; C57BL/KsJ) with different sensitivities of the β-cells to hyperglycaemia in vivo.
.
J Endocrinol.
1993;
136
289-296
-
10
McKillop A M, Abdel-Wahab Y HA, Mooney M H, O'Harte F PM, Flatt P R.
Secretion of glycated insulin from pancreatic B-cells in diabetes represents a novel aspect of B-cell dysfunction and glucose toxicity.
Diabetes and Metabolism.
2002;
28
3S61-3S69
-
11
Oda A, Bannai C, Yamaoka T, Katori T, Matsushima T, Yamashita K.
Inactivation of Cu, Zn-superoxide dismutase by in vitro glycosylation and in erythrocytes of diabetic patients.
Horm Metab Res.
1994;
26
1-4
-
12
O"Harte F PM, Abdel-Wahab Y HA, Conlon J M, Flatt P R.
Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells.
Biochim Biophys Acta.
1998;
1425
319-327
-
13
O"Harte F PM, Mooney M H, Kelly C M, Flatt P R.
Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation.
Diabetes.
1998;
47
1619-1624
-
14
Abdel-Wahab Y HA, O"Harte F PM, Barnett C R, Flatt P R.
Characterization of insulin glycation in insulin-secreting cells maintained in tissue culture.
J Endocrinol.
1997;
152
59-67
-
15
Abdel-Wahab Y HA, O’Harte F PM, Boyd A C, Barnett C R, Flatt P R.
Glycation of insulin results in reduced biological activity in mice.
Acta Diabetol.
1997;
34
265-270
-
16
McKillop A M, Mooney M H, Harriott P, Flatt P R, O’Harte F PM.
Evaluation of glycated insulin in diabetic animals using immunocytochemistry and radioimmunoassay.
Biochem Biophys Res Comm.
2001;
286
524-528
-
17
Lapolla A, Tessari P, Poli T, Valerio A, Duner E, Iori E, Fedele D, Crepaldi G.
Reduced in vivo biological activity of in vitro glycosylated insulin.
Diabetes.
1988;
37
787-791
-
18
Boyd A C, Abdel-Wahab Y HA, McKillop A M, McNulty H, Barnett C R, O’Harte F PM, Flatt P R.
Impaired ability of glycated insulin to regulate plasma glucose and stimulate glucose transport and metabolism in mouse abdominal muscle.
Biochim Biophys Acta.
2000;
1519
128-134
-
19
Hunter S J, Boyd A C, O’Harte F PM, McKillop A M, Wiggam M I, Ennis C N, Gamble R, Sheridan B, Barnett C R, McNulty H, Bell P M, Flatt P R.
Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic hyperinsulinemic clamp technique in man.
Diabetes.
2003;
52
492-498
-
20
McKillop A M, McCluskey J T, Boyd A C, Mooney M H, Flatt P R, O'Harte F PM.
Production and characterization of specific antibodies for evaluation of glycated insulin in plasma and biological tissues.
J Endocrinol.
2000;
167
153-163
-
21
Lindsay J R, McKillop A M, Mooney M H, O’Harte F PM, Bell P M, Flatt P R.
Demonstration of elevated concentrations of circulating glycated insulin in human type 2 diabetes using a novel and specific radioimmunoassay.
Diabetologia.
2003;
46
475-478
-
22
Lindsay J R, McKillop A M, Mooney M H, Flatt P R, Bell P M, O’Harte F PM.
Meal-induced twenty-four hour profile of circulating glycated insulin in type 2 diabetic subjects measured by a novel radioimmunoassay.
Metabolism.
2003;
52
631-635
-
23
Salacinski P R, McLean C, Sykes J E, Clement-Jones V V, Lowry P J.
Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha, 6 alpha-diphenyl glycoluril (iodogen).
Anal Biochem.
1981;
117
136-146
-
24
Stevens J F.
Determination of glucose by an automatic analyser.
Clin Chim Acta.
1971;
32
199-201
-
25
The Diabetes Control and Complications Trial Research Group .
Diabetes Control and Complications Trial (DCCT): results of feasibility study.
Diabetes Care.
1987;
10
1-19
-
26
Abdel-Wahab Y HA, O’Harte F PM, Ratcliff H, McClenaghan N H, Barnett C R, Flatt P R.
Glycation of insulin in the islets of Langerhans of normal and diabetic animals.
Diabetes.
1996;
45
1489-1496
-
27
Lindsay J R, McKillop A M, Mooney M H, O’Harte F PM, Flatt P R, Bell P M.
The effect of nateglinide on the secretion of glycated insulin and glucose intolerance in type 2 diabetes.
Diabetic Research and Clinical Practice.
2003;
61
167-173
-
28
Green B D, Gault V A, O’Harte , Flatt P R.
Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Curr Pharm Des.
2004;
10
3651-3662
-
29
Rudovich N N, Rochlitz H J, Pfeiffer A F.
Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients.
Diabetes.
2004;
53
2359-2365
Dr. Aine M. McKillop
School of Biomedical Sciences · University of Ulster
Coleraine BT52 1SA · Northern Ireland
Telefon: +44(28)70-323066
Fax: +44(28)70-324965
eMail: am.mckillop@ulster.ac.uk
